Skip to Main Content
Skip Nav Destination

First-in-Class IBI363 Shows Antitumor Effects in NSCLC

June 14, 2024

During yesterday’s June session of the ESMO Virtual Plenary (available at www.esmo.org), researchers announced that IBI363 (Innovent Biologics) showed effectiveness in a clinical trial in non–small cell lung cancer (NSCLC); results of trials testing the first-in-class PD-1/IL2α-bias bispecific antibody fusion protein in other solid tumors, including melanoma and colorectal cancers—initially presented at the American Society of Clinical Oncology 2024 Annual Meeting in early June—also demonstrated improved survival. Among 70 patients with wild-type NSCLC who received a dose of at least 0.3 mg/kg, most of whom had already tried two or more other treatments, the overall response rate (ORR) was 18.2% and the disease control rate was 69.7%. In the 37 patients with squamous cell carcinoma, all but one of whom had already tried anti-PD-(L)1 treatment, 13 had a partial response (PR); the ORR was 35.1% and the DCR was 75.5% after a median follow-up of about 5.6 months. And in nine patients who received IBI1363 at a dose of 3 mg/kg, all six patients with squamous NSCLC and one patient with adeno NSCLC experienced a PR; the ORR was 100% and 33.3%, respectively. The DCR for these seven patients was 100%.

Close Modal

or Create an Account

Close Modal
Close Modal